mebhydrolin napadisilate Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Mebhydrolin (INN) or mebhydroline is an antihistamine. It is not available in the United States, but it is in various other countries under the brand names Bexidal (BD) and Diazolin (RU). It is used for symptomatic relief of allergic symptoms caused by histamine release, including nasal allergies and allergic dermatosis.   Wikipedia

Chemistry

  • SMILES: CN1CCc2c(C1)c3ccccc3n2Cc4ccccc4
  • InChIKey: FQQIIPAOSKSOJM-UHFFFAOYSA-N
  • Mol. Mass: 276.38
  • ALogP: 3.68
  • ChEMBL Molecule:
    mebhydrolin  
More Chemistry

Pharmacology

Alternative names

1,5-naphthalenedisulfonic acid, compd. with 2,3,4,5-tetrahydro-2-methyl-5-(phenylmethyl)-1h-pyrido(4,3-b)indole (1:2) | 5-benzyl-1,3,4,5-tetrahydro-2-methyl-2h-pyrido(4,3-b)indole | diazolin | diazoline | diazolinum | fabahistin | incidal | mebhydrolin | mebhydroline | mebhydroline 1,5-naphthalenedisulfonate | mebhydrolin napadisilate | mebhydrolin napadisylate | napadisilate | omeril

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Hypersensitivity

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Coronary Artery Disease (Phase 4)

Hypersensitivity, Immediate ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue